CalciMedica (CALC) Competitors $2.76 -0.01 (-0.36%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CALC vs. PBYI, ELUT, TIL, BDTX, GALT, CGEN, TELO, MNPR, JATT, and ENTAShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Puma Biotechnology (PBYI), Elutia (ELUT), Instil Bio (TIL), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Compugen (CGEN), Telomir Pharmaceuticals (TELO), Monopar Therapeutics (MNPR), JATT Acquisition (JATT), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Puma Biotechnology Elutia Instil Bio Black Diamond Therapeutics Galectin Therapeutics Compugen Telomir Pharmaceuticals Monopar Therapeutics JATT Acquisition Enanta Pharmaceuticals CalciMedica (NASDAQ:CALC) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations. Does the MarketBeat Community favor CALC or PBYI? Puma Biotechnology received 535 more outperform votes than CalciMedica when rated by MarketBeat users. However, 93.75% of users gave CalciMedica an outperform vote while only 67.07% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformCalciMedicaOutperform Votes1593.75% Underperform Votes16.25%Puma BiotechnologyOutperform Votes55067.07% Underperform Votes27032.93% Does the media prefer CALC or PBYI? In the previous week, CalciMedica and CalciMedica both had 1 articles in the media. Puma Biotechnology's average media sentiment score of 1.45 beat CalciMedica's score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, CALC or PBYI? Puma Biotechnology has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$34.36M-$1.08-2.56Puma Biotechnology$243.57M0.55$21.59M$0.485.73 Do analysts rate CALC or PBYI? CalciMedica currently has a consensus target price of $19.33, indicating a potential upside of 600.48%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 154.55%. Given CalciMedica's higher probable upside, analysts plainly believe CalciMedica is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in CALC or PBYI? 61.3% of Puma Biotechnology shares are owned by institutional investors. 41.5% of CalciMedica shares are owned by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, CALC or PBYI? CalciMedica has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Is CALC or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to CalciMedica's net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -164.24% -103.53% Puma Biotechnology 9.56%41.60%10.71% SummaryPuma Biotechnology beats CalciMedica on 10 of the 15 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.35M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-2.5610.4289.5817.17Price / SalesN/A195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book1.945.094.774.78Net Income-$34.36M$151.83M$120.15M$225.60M7 Day Performance1.10%-2.13%-1.92%-1.23%1 Month Performance-20.00%-3.10%11.47%3.36%1 Year Performance-7.07%11.54%30.54%16.60% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica2.9517 of 5 stars$2.76-0.4%$19.33+600.5%-10.1%$37.35MN/A-2.5630Positive NewsPBYIPuma Biotechnology3.9504 of 5 stars$3.01+4.5%$7.00+132.6%-30.0%$147.76M$243.57M6.42185Positive NewsELUTElutia2.7375 of 5 stars$4.19+1.2%$10.00+138.7%+148.2%$144.81M$24.75M-1.59180TILInstil Bio2.8565 of 5 stars$22.18+1.0%$145.00+553.7%+196.5%$144.75MN/A-1.9149BDTXBlack Diamond Therapeutics2.3642 of 5 stars$2.54-0.8%$15.50+510.2%-16.2%$143.73MN/A-1.9290Positive NewsGap DownGALTGalectin Therapeutics1.9737 of 5 stars$2.29+8.3%$11.00+381.4%-39.2%$143.41MN/A-3.149News CoverageGap DownHigh Trading VolumeCGENCompugen1.5938 of 5 stars$1.59-1.6%$4.00+152.4%-17.3%$141.44M$59.85M80.5068TELOTelomir PharmaceuticalsN/A$4.76-8.5%N/AN/A$140.94MN/A0.001High Trading VolumeMNPRMonopar Therapeutics1.975 of 5 stars$26.68+5.1%$27.33+2.4%+1,165.4%$140.82MN/A-12.8810News CoverageGap UpJATTJATT AcquisitionN/A$8.16-24.1%N/A-51.6%$140.76MN/A0.003High Trading VolumeENTAEnanta Pharmaceuticals4.0505 of 5 stars$6.46+7.1%$19.50+201.9%-26.3%$136.91M$67.64M-1.10145 Related Companies and Tools Related Companies Puma Biotechnology Alternatives Elutia Alternatives Instil Bio Alternatives Black Diamond Therapeutics Alternatives Galectin Therapeutics Alternatives Compugen Alternatives Telomir Pharmaceuticals Alternatives Monopar Therapeutics Alternatives JATT Acquisition Alternatives Enanta Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALC Stock Alerts